– Scientific collaborators from Stanford University will present preclinical data on the sensitivity of [18F]OP-801 versus TSPO-PET to detect neuroinflammation at an early stage –
REDWOOD CITY, Calif., July 18 12, 2022 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel therapeutic hydroxy dendrimers, today announced a poster presentation of preclinical data on the sensitivity of its hydroxy dendrimer. PET-based tracer, [18F]OP-801, relative to the 18 kDa translocator protein [TSPO]-PET, using [18F]GE180 (TSPO-PET), an established PET imaging approach for the detection of neuroinflammation, in a mouse model of Alzheimer’s disease. The data will be presented by collaborating scientists from Stanford University in a poster at the 2022 Alzheimer’s Association International Conference (AAIC) to be held at the San Diego Convention Center in San Diego, California, and online, from July 31 to August 4, 2022.
Details of the poster presentation can be found below:
Title: New PET tracer based on hydroxyl dendrimer [18F]OP-801 detects early stage neuroinflammation in 5xFAD mouse model with higher sensitivity than TSPO-PET
Poster number: 60700
Poster session: P1-07 Biomarkers: Neuroimaging
Presenter: Mackenzie Carlson, NSF graduate researcher at Stanford University School of Medicine
Date hour : Sunday, July 31, 2022, 9:15 a.m. to 4:45 p.m. PT
Location: San Diego Convention Center Exhibit Hall
[18F]OP-801 is a hydroxyl dendrimer-based neuroimaging agent being developed as a companion biomarker and pharmacodynamic tool for therapeutics to treat neuroinflammation due to neurodegenerative diseases including Alzheimer’s disease and lateral sclerosis. amyotrophic (ALS). This imaging agent was designed to cross the blood-brain barrier – a highly selective membrane that blocks most molecules from reaching the brain and spinal cord – in the presence of inflammation and to enter active microglial cells to that they can be seen in the pictures. [18F]OP-801 has been shown to be selectively (>95%) taken up by reactive macrophages/microglia.1 [18F]OP-801 shows promise for visualizing the progression of neuroinflammation with high specificity and sensitivity, warranting clinical investigation. A phase 1/2 clinical trial of [18F]OP-801 is currently being tested in healthy volunteers and ALS patients.
About Ashvattha Therapeutics
Ashvattha Therapeutics is a clinical-stage biotechnology company developing novel hydroxylated dendrimer (HDT) therapeutics targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology. The therapies are based on hydroxyl dendrimers (HD), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan of Johns Hopkins University. HDs chemically conjugated with disease-modifying drugs create new proprietary HD therapies (HDTs) that selectively target reactive inflammatory cells in diseased tissues with long-lasting localized effects. Ashvattha has initiated several programs with HDTs focusing on neurology, ocular neovascular diseases including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases. For more information, visit: www.avttx.com.
1 Henningfield, CM, Cleland, JL, Sharma, R., Green, KN Selective targeting of plaque-associated microglia by systemic dendrimer administration in a model of Alzheimer’s disease. Alzheimer’s and dementia. 2020; Volume 16. Number S2. https://doi.org/10.1002/alz.040661